Aurobindo Pharma receives final approval for Ondansetron Orally Disintegrating Tablets

13th April 2010

Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Ondansetron Orally Disintegrating Tablets (ODT) USP 4mg and 8mg from the US Food & Drug Administration (USFDA).

Ondansetron ODT 4mg and 8mg are the generic equivalent Glaxo SmithKline's Zofran® ODT 4mg and 8mg.

Ondansetron ODTs are antiemetics and indicated for prevention of nausea and vomiting in patients undergoing chemotherapy, radiation therapy or surgery. The product is ready for launch.

Aurobindo has a total of 115 ANDA approvals (86 Final approvals and 29 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com